Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -1.72% 28.50p 28.00p 28.50p 29.25p 27.50p 29.00p 309,351 14:27:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -32.7 -28.3 - 74.99

Motif Bio Share Discussion Threads

Showing 1451 to 1471 of 1475 messages
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
DateSubjectAuthorDiscuss
15/8/2017
15:55
Been picking up a few more of these.
someuwin
14/8/2017
15:19
Can anybody help me out as i am trying to understand the ISIN number of the warrants traded on the nasdaq as thinking of buying a few Much appreciated if anybody has any info or can point me in the right direction
slider27
11/8/2017
17:52
What are the chances that this will be an independent concern going into 2018?
dstorey1
10/8/2017
09:07
I absolutely take your point ilovetowin but if he key milestones continue to come in, on time and positive then at some point this has to move. I'm at a loss why it's so undervalued compared to peers but so far it's delivering in terms of the product and science.
razmo1
10/8/2017
09:02
Need to chill out and come back at end of September as this isn't going anywhere in meantime by looks of it.
blueblood
10/8/2017
08:48
Key milstone. Hmmm.Didn't we have a "key milstone" in April?Positive data readout? And a US25 million dollar raise at 30pOh and let's not forget giving Mr Bertoldi a front hander of 125,000 dollars to keep AMP from dumping and destroying the share price Yes LPO was indeed a key milstone.We've had many if those.29p bid.
ilovetowin
10/8/2017
08:34
It's Revive2 readout we are waiting for and LPO is key milestone and means countdown is on with results expected in around 6-8 weeks from now.
blueblood
10/8/2017
08:16
LPO everyone was waiting for. Speculation on the dates. The tension. The hope. The result: Nada. 29 bid.
ilovetowin
09/8/2017
11:14
Back in with speculative buy, even after previous misgivings regards US IPO. GLA.
dstorey1
09/8/2017
10:38
Few on here following? Happy to buy back in at 29p. Be interesting to see how Nasdaq responds.
waterloo01
04/8/2017
21:18
Seems more than happy trading well below the big placing priceNo idea why it's trading like this after such huge news effectively derisking the company Big shame.
ilovetowin
04/8/2017
19:30
Still in Banshee but awaiting revive 2 to do the talking!I've been adding
drmaccers
27/7/2017
15:20
Just buy these pull backs Sir!
ny boy
25/7/2017
16:32
It seems to be slowly slipping down further and further.
philoosh
20/7/2017
15:15
Won't final results and potential FDA approval for Iclaprim be known in the first half of 2018? Maybe closer to then the share price will react more strongly?
nick rubens
20/7/2017
12:59
Big disappointment here
ilovetowin
19/7/2017
20:17
"If you want a small antibiotic company whose products have some real prospect, I'd look at Tetraphase in the US" That sounds suspiciously like a tip to me Vulgaris. See you on LSE hopefully. Ivyspivey and Dr Maccers, who seems to be on sabbatical, and used to post on here occasionally, are the relevant professionals there.
banshee
19/7/2017
19:57
I don't think I tipped them, but what I would say is that Tetraphase have some very interesting chemistry for modifying tetracyclines. They can synthesise large numbers of different molecules whereas, previously, this was difficult and slow. Their mistake, with their lead molecule, eravacycline, was an iv/oral switch trial in UTI. Patients who switched early tended to fail, the implication being that that oral wasn't giving adequate levels.... They're now doing another cUTI trial with iv only. I'll look at the LSE board.
vulgaris
19/7/2017
16:44
Ah Vulgaris, I wondered where you had got to. All the action on this one is on the LSE BB, where you could debate with other industry professionals, it is pretty much a graveyard here. Meanwhile, didn't you tip Tetraphase just before it crashed 90% or so? Or was that someone else?
banshee
19/7/2017
16:30
Banshee: apropos delafloxacin. Its merit is scope for iv to oral switch. As you note it's a fluoroquinolone; several fluoroquinolones have come unstuck post-licensing owing to rare toxicities but others (cipro- and levo-) have been highly successful. Only time will tell... HABP trials for any antibiotic are more costly than ABSSSI as harder to recruit patients..... fewer cases and more excluded owing to having already received other agents.
vulgaris
18/7/2017
13:22
REVIVE-2 has finished recruiting, so Last Patient Out should be RNS announced in a week or so. The Pacyhderm in the Pantry however, remains the potential requirement for further funding re INSPIRE.
banshee
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170817 13:45:17